While more research is needed, obesity does play a role in the response to viral infections as well as immunizations, said Kara Dupuy-McCauley, MD, a pulmonologist at the Mayo Clinic in Rochester, Minnesota.
Obesity, which is widespread in the United States, impacts the response to viral infections as well as immune response to vaccines, said Kara Dupuy-McCauley, MD, a pulmonologist at the Mayo Clinic in Rochester, Minnesota, who spoke at CHEST 2022.
Transcript
What is the impact of obesity on viral infections and immunizations?
Well, to summarize the impact of obesity on viral infections and immunizations, I think that we do probably need to do a little bit more work to understand exactly what the impacts are, especially when it comes to obesity and immunizations, because I think that body of literature has a little bit more contradictory information. But I think that it's safe to say that obesity does increase the risk of contracting a viral infection, at least in the specific viral infections where it has been studied. And, it's widely known that obesity also increased the risk of morbidity and mortality as a result of viral infection.
And I think, based on the research that I've done, there probably is a difference in in vaccine response just because of the immunity impairment that comes along with obesity. But I think we do need a little bit more research to understand exactly what the impact is.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More